The Food and Drug Administration (FDA) has approved the first vaccine for pregnant women to prevent RSV in infants, the agency announced on Monday. Abrysvo is made by Pfizer.

The FDA had previously approved Pfizer's Abrysvo vaccine only for use in older adults. Adults ages 60 and older are recommended to talk to their doctors about potentially getting the shot.

FDA greenlights maternal RSV vaccine, representing a major step in protecting young babies Abrysvo was also approved by the FDA in May 2023 to prevent RSV illness in adults 60 years and older ...

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age.

The Food and Drug Administration (FDA) on Monday approved the first vaccine meant to prevent infections in infants, with the new drug designed to be administered to pregnant mothers in their third ...

Abrysvo has been approved as a maternal vaccine to prevent lower respiratory tract disease (LRTD) in babies from birth through 6 months of age, according to the FDA’s press release.

T he FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus ...

T he US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo to include adults aged 18–59 years who have chronic ...

The FDA recently approved Abrysvo, a respiratory syncytial virus vaccine, as the first vaccine approved for use in pregnant individuals to prevent RSV lower respiratory tract disease in infants ...

The Abrysvo shots considered by the FDA advisers Thursday are the same as the Pfizer shot only narrowly backed by this same committee for use in adults 60 and older at a meeting earlier this year.

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

About ABRYSVO Regulatory Review On March 24, 2022, Pfizer announced the FDA granted Breakthrough Therapy Designation for ABRYSVO for the prevention of lower respiratory tract disease caused by RSV ...